|Day Low/High||49.12 / 49.49|
|52 Wk Low/High||36.81 / 50.24|
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.
- All subgroups treated with Soliqua 100/33 achieved a mean HbA1c of below 7 percent after 30 weeks -
- New DELIVER 3 Real-World Toujeo® Observational Study Confirms Reduction of Hypoglycemia in Real-Life Setting -
Plus more from the biotechnology world on Wednesday, June 7.
The magnetic tape cartridges in the company's products will be under review.
The cybersecurity firm deemed it 'highly likely' that a group of hackers working with North Korea was behind the attack.
The legislation would also force companies to announce planned price hikes.
The Tarrytown, N.Y.-based biopharmaceutical firm had first-quarter revenue of $1.32 billion.
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Large pharmaceutical companies could be interested in buying the drug company, but even if a deal isn't forthcoming an activist investor could seek to elect directors and make one happen
Sarepta CEO Ed Kaye said he's stepping down.
Sarepta Therapeutics and Vertex Pharmaceuticals and Endo Pharmaceuticals were among the biotech stock movers Friday morning.
The timing of these two departures could be coincidental and mean nothing, or they might signal Sanofi's interest in acquiring Sarepta.
Jim Cramer is bullish on Wingstop, Sanofi, Micron Technology and Nisource.
True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.
Whether you loved the original or not, these sequels are making their way to a theater near you.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:
K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio ® (teriflunomide) on cortical gray matter atrophy in patients...
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today positive new six-year investigational data from a post-hoc analysis of the extension study of Lemtrada ® (alemtuzumab) in...
- Monthly dosing schedule now approved in both United States and European Union -
Monthly dosing schedule now approved in both United States and European Union
Two sexual harassment scandals might devastate other brands, but not so with Fox News.
French multinational pharmaceutical company Sanofi on Monday filed a lawsuit against U.S. company Mylan.
Sanofi's Valproate is manufactured in France.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.